Persistent residual inflammatory risk at 1 month after contemporary PCI: rationale for routine hsCRP reassessment and dual-target therapy
-
By
-
Xinwang Gong
-
Chang Zhou
-
Yutao Wu
-
May 1, 2026
-
0 min